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Abstract Prion diseases, traditionally referred to as transmissible spongiform en-
cephalopathies (TSE), are invariably fatal and highly infectious neurodegenerative
diseases that affect a wide variety of mammalian species, manifesting as scrapie in
sheep, bovine spongiform encephalopathy (BSE, or ‘mad-cow’ disease) in cattle, and
Creutzfeldt-Jakob disease (CJD), Gerstmann-Strussler-Scheinker syndrome(GSS),
Fatal familial insomnia (FFI) and Kulu in humans, etc. These neurodegenerative
diseases are caused by the conversion from a soluble normal cellular prion pro-
tein (PrPC) into insoluble abnormally folded infectious prions (PrPSc). The hy-
drophobic region PrP(109–136) controls the formation into diseased prions: the nor-
mal PrP(113–120) AGAAAAGA palindrome is an inhibitor/blocker of prion diseases
(Mol Cell Neurosci 15: 66–78), and the highly conserved glycine-xxx-glycine motif
PrP(119–131) can inhibit the formation of infectious prion proteins in cells (J Biol
Chem 285: 20213-20223). This article gives detailed reviews on the PrP(109–136)
region and presents the studies of its three-dimensional structures and structural
dynamics.
Keywords: hydrophobic region; PrP(109-136); AGAAAAGA palindrome; glycine-xxx-
glycine motif; molecular dynamics study
1 Introduction
Prion diseases such as Creutzfeldt-Jakob disease (CJD) in humans and bovine spongiform
encephalopathy (BSE or ‘mad-cow’ disease) in cattle are invariably fatal neurodegenera-
tive diseases. Prions differ from conventional infectious agents in being highly resistant
to treatments that destroy the nucleic acids found in bacteria and viruses. The infectious
prion is thought to be an abnormally folded isoform (PrPSc) of a host protein known as
the prion protein (PrPC). The conversion of PrPC to PrPSc occurs post-translationally and
involves conformational change from a predominantly α-helical protein to one rich in
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β-sheet amyloid fibrils. Much remains to be understood about how the normal cellular
isoform of the prion protein PrPC undergoes structural changes to become the disease as-
sociated amyloid fibril form PrPSc. The hydrophobic domain of PrPC(109–136) is highly
conserved, containing a palindrome and the repeats of the GxxxG protein-protein inter-
action motif (two glycines separated by any three residues; please note that the minimum
number of residues to form fibrils should be 5 [1]). It is reported that the palindrome
AGAAAAGA is an inhibitor/blocker of prion diseases [1, 2] and the glycine-xxx-glycine
motif GAVVGGLGGYMLG is also an inhibitor of prion diseases [3, 4, 5]. The alterations
of residues in AGAAAAGA and GAVVGGLGGYMLG will drastically affect the ability
of cells and lead to the amyloid fibril formations (e.g. A117V will cause the Gerstmann-
Straussler-Scheinker prion disease, and the numerous mutants in [3]). Our computational
results also confirm the amyloid fibril formation ability of the PrP(109–136) hydrophobic
region (Figure 1). As shown in Figure 1, if energy is less than the threshold energy -26
Figure 1: Identifying the amyloid fibril formation property in PrP(109–136) re-
gion by the fibril prediction program of [6].
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kcal/mol then amyloid fibril is formed in the corresponding region of residues, thus, the
palindrome segment PrP(113–120) and the GLGGY segment PrP(124–128) can be firmly
confirmed having a strong amyloid fibril formation property. This paper will give detailed
reviews on the PrP(109-136) region from the 3D molecular structure (Figure 2) point of
view and presents the studies of its molecular structural dynamics. The rest of this paper is
Figure 2: The 3D molecular structure of human PrP. (A): the 3D molecular NMR
structure of human PrP(110-136) in dodecylphosphocholine micelles. (B): the 3D
molecular NMR structure of human PrP(125–228).
arranged as follows. Section 2 will give a survey of the research works on AGAAAAGA
and present the 3D structure of amyloid fibrils in the AGAAAAGA segment. Then, in
Section 3, the analysis of the glycine-XXX-glycine motif GAVVGGLGGYMLG inhibit-
ing prion diseases will be done from the molecular structural point of view. Section 4 will
make some concluding remarks on the hydrophobic PrP(109–136) region.
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2 Studies on the PrP(113–120) AGAAAAGA
2.1 A Survey of the Research Works on AGAAAAGA
The highly conserved hydrophobic palindrome AGAAAAGA PrP(113–120) has been
considered essential to PrP conformational conversion. Firstly we give a survey of the re-
search works on prion AGAAAAGA listed in the PubMed database (www.ncbi.nlm.nih.gov).
The C-terminally-truncated human prion protein variant Y145Stop (i.e. HuPrP(23-
144)) is a valuable model for understanding the fundamental properties of amyloid for-
mation. To examine the role of AGAAAAGA segment in fibrillization of PrP(23-144), a
deletion variant ∆(113-120) PrP(23-144) (in which the palindrome sequence is missing)
is used [7]. The deletion results in an altered amyloid β-core without affecting amyloido-
genicity or seeding specificity; this concludes that the core of some amyloids contains “es-
sential” (nucleation-determining) and “nonessential” regions, with the latter being flexible
in amino acid sequence space [7].
The amyloid fibrils formed by the polypeptides of PrP(113–127), AGAAAAGAVVG-
GLGG, are taken as the model compound to investigate the biophysical principles gov-
erning the steric zipper amyloid fibril formation [4, 5, 8, 9]. The target fibrils adopt the
structural motif of Class 7 steric zipper, which is formed by stacking of antiparallel β-
sheet layers with residue 117 + k forming backbone hydrogen bonds to residue 120 − k
[4, 5, 8].
Computer simulations of amyloid fibril formation by the Syrian hamster prion pro-
tein (SHaPrP) residues AGAAAAGA, the mouse prion protein (MoPrP) residues VA-
GAAAAGAV, and their variations GA6G (a longer uninterrupted Alanine stretch flanked
by Glycine), (AG)4 (a complete disruption of hydrophobic residues), A8, GAAAGAAA (a
mimic of Aβ(29-36)), A10, V10, GAVAAAAVAG (uninterrupted hydrophobic sequence),
VAVAAAAVAV (less flexible than MoPrP(111-120)) are studied in [10]. The first two
peptides are thought to act as the velcro that holds the parent prion proteins together in
amyloid structures and can form fibrils themselves [10].
AGAAAAGA of HuPrP(105–210) is reported being involved into the oligomerization
and engaged in intra- and/or inter-molecular interactions [11]. The SHaPrP(109–122)
peptide near the AGAAAAGA region is observed to form steric zipper fibrils by the data
of crystal solid-state NMR and molecular dynamics (MD) [5].
The cellular isoform of the prion protein PrPC is located at the cell membrane. Studies
have shown that exposure of cells to copper (Cu) causes internalisation of PrPC in vitro,
and deletion mutation studies have shown that the palindromic region, amino acids 113-
120 with the sequence AGAAAAGA is essential for copper-induced internalisation to
occur [12]. Kourie et al (2003) studied the copper modulation of ion channels of PrP(106–
126) mutant prion peptide fragments and found that the hydrophobic core AGAAAAGA
is not a Cu2+-binding site (but at Met 109 and His ll1 ion channels can be formed) [13].
The AGAAAAGA palindrome in PrP is required not only for the attainment of the
PrPSc conformation but also to generate a productive PrPSc-PrPC complex that leads to
the propagation of PrPSc [14]. In contrast to wild type (wt) PrP, PrP lacking the palin-
4
drome (PrP ∆(112-119)) neither converted to PrPSc nor generated proteinase K-resistant
PrP. In [14], we also know that synthetic peptides corresponding to the so-called “toxic
peptide” PrP(106-126) segment form fibrils in solution with β-sheet structure, suggesting
that PrP(106–126) segment may feature in PrPSc-PrPC associations, and larger peptides
of PrP(107-142) antagonize the in vitro conversion of PrPC to the protease-resistant state
in a cell-free conversion model.
Zanuy et al (2003) reported that, for AGAAAAGA, the antiparallel strand orientation
is preferred within the sheets but the parallel orientation is preferred between sheets [15,
16]. AGAAAAGA is one of the most highly amyloidogenic peptides and oligomers of
AGAAAAGA were found to be stable when the size is 6 to 8 (hexamer to octamer) [16].
Here the AGAAAAGA model of [16] used for their MD is a homology structure.
In [17], the following bioinformatics on AGAAAAGA is known. AGAAAAGA dis-
plays the highest tendency to form amyloid. Peptides containing AGAAAAGA are toxic
to neurons in culture, whereby the sequence AGAAAAGA was found to be necessary
but not sufficient for the neurotoxic effect [1]. The synthetic peptides derived from the
central part of PrPC(106–141) have an inhibitory effect on this conversion of PrPC to PK-
resistant PrPSc. The presence of residues 119 and 120 (the two last residues within the
motif AGAAAAGA) seems to be crucial for this inhibitory effect. Mutant PrP molecules
carrying deletions of amino acids 108–121 or 114–121 are not convertible to PrPSc; there-
fore, the central hydrophobic region, spanning all or most of the sequence AGAAAAGA,
plays an important role in the PrPSc-PrPC conversion process. Wegner et al (2002) as-
sessed the effect of mutations at and around the AGAAAAGA hydrophobic sequence on
protease resistance and found that mutations in the central AGAAAAGA hydrophobic
region lead to immediate alterations in PrP structure and processing [17].
The amyloidogenic and hydrophobic core AGAAAAGA has been implicated in mod-
ulation of neurotoxicity and the secondary structure of PrP(106-126) [18, 19], which is
dependent on the formation of aggregated fibril structures regulated by the AGAAAAGA
core [18].
Brown (2000) reported that AGAAAAGA blocks the toxicity of PrP(106-126), sug-
gesting that this sequence is necessary (but insufficient) for the interaction of PrP(106-
126) with neurons and targeting or use of the AGAAAAGA peptide may represent a
therapeutic opportunity for controlling prion disease [1].
HuPrP(106-126) has been shown to be highly fibrillogenic and toxic to neurons in
vitro. Jobling et al (1999) found that the AGAAAAGA PrP(113–120) hydrophobic core
sequence is important for PrP(106-126) toxicity probably by influencing its assembly into
a neurotoxic structure and the hydrophobic sequence may similarly affect aggregation and
toxicity observed in prion diseases [19].
Chabry et al (1998) reported that peptides from the central part of the hamster PrP
106–141 (where residues in the vicinity of positions 106-141 of PrPSc and/or PrPC are crit-
ically involved in the intermolecular interactions that lead to PrPSc formation) could com-
pletely inhibit the conversion induced by preformed PrPSc and the presence of residues
119 and 120 from the highly hydrophobic sequence AGAAAAGA (PrP(113–120)) was
crucial for an efficient inhibitory effect [20].
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Holscher et al (1998) reported that the presence of AGAAAAGA of mouse PrPC plays
an important role in the conversion process of PrPC into PrPSc and that a deletion mutant
lacking these codons indeed behaves as a dominant-negative mutant with respect to PrPSc
accumulation [2].
PrP AGAAAAGA is the most highly amyloidogenic peptide and is conserved across
all species [21, 22]. Gasset et al (1992) reported there are similarities between the PrP
sequence AGAAAAGA and that of silkworm fibroin, and the homology between PrP
sequence AGAAAAGAVVGGLGG and that of spider fibroin [21]. Thus, we may say
that the hydrophobic region of PrP(109–136) should be a region to form β-sheets and
amyloid polymers, instead of α-helices of the Garnier-Robson analysis [23].
2.2 3D Structure of Prion AGAAAAGA Amyloid Fibrils
Seeing the above survey, we know that prion AGAAAAGA peptide has been reported to
own an amyloid fibril property (initially described in 1992 by Gasset et al of Prusiner’s
Group). However, there has not been traditional X-ray or NMR experimental structural
bioinformatics for this octapeptide yet, due to the unstable, noncrystalline and insoluble
nature of this region, which just falls within the N-terminal unstructured region of prion
proteins. Studies on atomic-resolution structures of the AGAAAAGA peptide will prove
useful in future experimental studies on this region, aspects of the structure or the dy-
namics of this region should play a role in the aggregation process, and knowledge of
these may be useful for the goals of medicinal chemistry for controlling prion diseases.
Zhang (2011) successfully constructed three amyloid fibril models (denoted as Models
1–3) for the PrP(113–120) AGAAAAGA region [24]. Using all the PDB templates of
[8] (with PDB IDs: 2OKZ, 2ONW, 2OLX, 2OMQ, 2ON9, 2ONV, 2ONA, 1YJO, 2OL9,
2OMM, 2ONX, 2OMP, 1YJP), simulation conditions are completely consistent with the
experimental works of [8] and the simulation methods of package Amber 10 [25] are:
the optimization steepest descent (SD) method and conjugate gradient (CG) method to
relax the Models, then the standard simulated annealing method to make the equilibra-
tion of Models sufficiently stable and then the SD-CG optimization methods to refine
the Models. Model 1 and Models 2–3 belong to Class 7 and 1 of [8] respectively, i.e.
Model 1 is β-strand antiparallel, face=back, up-up (Figure 3) (where numerical results
show the agreement with [4, 16]), and Models 2–3 are β-strand parallel, face-to-face,
up-up (Figures 4–5). In all these models, there is about 5 angstroms between the two
closest adjacent β-sheets, maintained by hydrophobic bonds, and about 4.5 angstroms
between the two closest adjacent β-strands, which are linked by hydrogen bonds. Illumi-
nated by PDB templates 3FVA, 3NHC/D, 3NVF/G/H/E, 3MD4/5, 2OMP, computational
approaches of global optimization, local search energy minimization (EM), simulated an-
nealing (SA) and structural bioinformatics etc or introducing novel mathematical formu-
lations and physical concepts into molecular biology may allow us to obtain a description
of the protein 3D structure at a submicroscopic level for prion AGAAAAGA amyloid
fibrils [24, 26, 27, 28, 29, 30].
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Figure 3: Model 1. (A): blue dashed lines denote the hydrogen bonds between
the pairs of β-strands, and the β-sheets are maintained by van der Waals contacts
and hydrophobic packings. (B): the red circle denotes there are very few water
molecules in this part of the truncated octahedral box of TIP3P waters, the tra-
jectories of the movement of the amyloid fibril formulate a “cage” made of waters
and the amyloid fibril flies to the bottom of the “cage”, the mouth of the “cage’ is
open – this illuminates to us the amyloid fibril is very hydrophobic.
3 Structural Studies on the PrP(119–131) GAVVG-
GLGGYMLG
Some 30 segments from the Alzheimer’s amyloid-β (Aβ) and tau proteins, the PrP prion
protein, insulin, etc form amyloid-like fibrils, microcrystals that reveal steric zipper struc-
tures [8]. Harrison et al (2006) reported there are similarities between Aβ and PrP in the
segment of the three GxxxG repeats (where both Aβ and PrP have the crucial residue
Methionine located in the middle (GxMxG) of the last repeat) [31, 32] that controls prion
formation [3]. Harrison et al (2010) used cell biological approaches of investigating nu-
merous mutants in this region to reveal the mechanism of prion inhibition, and mutage-
nesis studies demonstrate that minor alterations to this highly conserved region of PrPC
drastically affect the ability of cells to uptake and replicate prion infection in both cell and
animal bioassay [3]. This section presents some explanations for the biological experi-
mental performance of [3] from the molecular structural point of view.
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Figure 4: Model 2. (A): blue dashed lines denote the hydrogen bonds between
the pairs of β-strands, and the β-sheets are maintained by van der Waals contacts
and hydrophobic packings. (B): the red half-circles denote there are very few
water molecules in this parts of the truncated octahedral box of TIP3P waters,
the trajectories of the movement of the amyloid fibril formulate a “cage” made
of waters with two open “mouths” circled in red – this illuminates to us that the
hydrophobic property of amyloid fibrils can form a very interesting movement
pattern of trajectories.
First, we do the alignments of the structured region of mouse, human, dog, rab-
bit, horse and elk PrPC (with PDB IDs 1AG2, 1QLX, 1XYK, 2FJ3, 2KU4, 1XYW re-
spectively) (Figure 6). Figure 6(A) shows the PrP(125–136) 3D structures of human,
dog, rabbit, horse and elk superposed onto mouse with backbone-atom-RMSD values
2.579427, 2.228940, 2.745877, 2.532690, 2.877734 angstroms respectively. In Figure
6(B), the alignment of sequences was generated by the online CLUSTAL 2.1 program
at http://www.ebi.ac.uk/Tools/msa/clustalw2/, where “*” means that the residues or nu-
cleotides in that column are identical in all sequences in the alignment, “:” means that
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Figure 5: Model 3. (A): blue dashed lines denote the hydrogen bonds between
the pairs of β-strands, and the β-sheets are maintained by van der Waals contacts
and hydrophobic packings. (B): the red half-circles denote there are very few
water molecules in this parts of the truncated octahedral box of TIP3P waters,
the trajectories of the movement of the amyloid fibril formulate a “cage” made
of waters with two open “mouths” circled in red – this illuminates to us that the
hydrophobic property of amyloid fibrils can form a very interesting movement pat-
tern of trajectories, and this also illuminates us the property of periodic boundary
calculations in PMEMD (particle mesh eward molecular dynamics) simulations.
conserved substitutions have been observed, “.” means that semi-conserved substitutions
are observed, the red colored residues are Small (small+ hydrophobic (incl.aromatic -
Y)), the blue colored residues are Acidic, the green colored residues are Hydroxyl +
sulfhydryl + amine + G, and the gray colored residues are Unusual amino/imino acids
etc; the residue numbers are from 119 to 231 (for rabbit the numbers are 1 less than oth-
ers); the last column of numbers denotes the number of residues accounted from 1; the
PrP 125–136 LGGYMLGSAMSR, β-strand 1 (β1), α-helix 1 (α1), β-strand 2 (β2), α-
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helix 2 (α2) and α-helix 3 (α3) of a PrP structure (Figure 2(B)) were underline denoted.
In Figure 6, we can see the PrP(125–136) LGGYMLGSAMSR is highly conserved
Figure 6: The alignments of the structured region of mouse, human, dog, rab-
bit, horse and elk proteins with PDB IDs 1AG2, 1QLX, 1XYK, 2FJ3, 2KU4,
1XYW respectively. (A) shows the 3D structural alignments of PrPC(125–136)
(whose residues were underlined in (B)). (B) shows the 1D sequence alignments
of PrPC(119–231).
among all species, strongly suggesting it has functional and evolutionary significance. To
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understand the functions of proteins at a molecular level, in protein structures, the non-
covalent interactions such as hydrogen bonding (HB), ionic interactions (SB), van der
Waals forces (vdW), and hydrophobic packing (HP) are driving the proteins to be able to
perform their biological functions (http://en.wikipedia.org/wiki/Protein structure). Thus,
in the below, we will investigate the HBs, SBs, vdWs, HPs in the structures and their
structural dynamics of LGGYMLGSAMSR of human and rabbit, GLGGYMLGSAMSR
of mouse, VVGGLGGYMLGSAMSR of elk and dog, GSVVGGLGGYMLGSAMSR of
horse (where S120 is special for horse, instead of A120) and structural connections with
other residues/loops/sheets/helices in the C-terminal. Mutations will destroy these non-
covalent interactions that well maintain the structure so the function of the prion protein.
This will give clear explanations to the mutants in the Glycine-rich region of [3, 33],
which affect the uptake of prion infectivity very much.
In 2010, horses were reported to be resistant to prion diseases [34]. First, we analyze
the role of GSVVGGLGGYMLGSAMSR (PrP(119–136)) in horse PrPC(119–231) (PDB
entry 2KU4). In our study [35], the MD simulation conditions are at 350 K in explicit sol-
vent under neutral and low pH environments, heatings are using the Langevin thermostat
algorithm in constant NVT ensembles and the equilibrations and productions are using
Langevin thermostat algorithm in constant NPT ensembles. Seeing the Tables I–III of the
Supplementary Material of [35], we know the following HBs of GSVVGGLGGYML-
GSAMSR (PrP(119–136)):
ARG136-TYR157 (linking β1-to-α1 loop with α1-to-β2 loop, 68.27%, 71.04%),
MET134-ASN159 (linking β1-to-α1 loop with α1-to-β2 loop, 29.83%, 21.47%),
GLY131-GLN160 (linking β1 with β2, 26.67%, 37.03%),
SER132-GLN217 (linking β1 with α3, 29.70%, 12.90%),
ARG136-PRO158 (linking β1-to-α1 loop with α1-to-β2 loop, 9.53%, 6.01%),
ARG136-TYR157 (linking β1-to-α1 loop with α1-to-β2 loop, 68.27%, 71.04% ),
GLY126-ARG164 (linking bend before β1 with β2-to-α2 loop, 33.31%1),
TYR128-ASP178 (linking coil before β1 with α2, 11.81%1),
SER120-LEU125 (in the peptide, 9.72%1),
LEU125-10TYE128 (in the peptide, 5.58%2),
GLY119-4VAL122 (in the peptide, 6.51%2),
GLY127-ARG164 (link bend before β1 with β2-to-α2 loop, 5.87%2),
where the first percentage is for seed1 (%1) and the second percentage is for seed2 (%2)
and the two seeds mean two different initial velocities of 30 ns MD, and the following
HPs of GSVVGGLGGYMLGSAMSR (PrP(119–136)):
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In PrP(119–136) of 2LBG.pdb, between the two adjacent residues there are always
occupied by HPs with rate of 100%, except for between GLY123 and GLY124, and
between GLY126 and GLY127,
Among the residues in PrP(119–136), there are HPs in
TYR128–LEU130 (where LEU130 is a residue in β1),
VAL121–GLY119, GLY123, TYR128, MET129, LEU130 (where MET129
and LEU130 are in β1),
VAL122–SER120, GLY124, LEU125, TYR128,
GLY123–SER120, LEU125,
TYR128–GLY126,
MET129–GLY131 (where both MET129 and GLY131 are in β1),
MET134–SER132, ARG136 (where SER132 is in β1),
The HPs between a residue in PrP(119–136) and a residue in PrP(137–231):
SER135–PRO137 (where SER135, PRO137 is in β1-to-α1 loop),
ARG136–MET154, TYR157 (where ARG136 is in β1-to-α1 loop, MET154
and TYR157 are in α1-to-β2 loop),
ASN159–SER135, ALA133, ARG136, MET134 (where ASN159 is in α1-
to-β2 loop),
TYR162–TYR128, MET129, LEU130 (where MET129, LEU130 are in β1,
and TYR162 is in β2, there is no HB between TYR162 and LEU130),
GLN217–GLY131 (where is in β1, GLN217 is in α3),
ARG164–GLY127, MET129, TYR128 (where MET129 is in β1, ARG164
is in β2-to-α2 loop),
TYR163–TYR128, LEU130, MET129 (where MET129, LEU130 are in β1,
TYR163 is in β2),
GLN162–ALA133, LEU130, MET134, GLY131, SER132 (where ALA133,
LEU130, GLY131, SER132 are in β1, GLN162 is in β2),
VAL161–GLY131, LEU130 (where GLY131, LEU130 are in β1, VAL161 is
in β2),
MET213–MET134 (MET213 is in α3, MET134 is in the β1-to-α1 loop),
with > 50% occupancy rate over the long MD trajectory of 30 ns. The mutations listed in
[3] will break these HBs and HPs to lose the inhibition to prion diseases of horses.
Rabbits are also resistant to infection from prion diseases from some species [36, 37,
38, 39, 40] and the outbreak of “mad rabbit disease” is unlikely [41, 42]. Nisbet et al
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(2010) reported there is 87% sequence homology between mouse PrP and rabbit PrP, ap-
proximately 9 of the 33 (i.e. 1/3) of the difference in the region DGRRSSSTV of mouse
and QRAAGVL of rabbit, and residues surrounding the glycosylphosphatidylinositol an-
chor attachment site of PrP modulate prion infection [43]. Under the MD simulation
conditions of 450 K in explicit solvent, neutral and low pH environments, with heatings
using the Langevin thermostat algorithm in constant NVT ensembles and the equilibra-
tions and productions using Langevin thermostat algorithm in constant NPT ensembles,
we have found rabbit PrP has the C-terminal residue R227 forming a HB/SB network
with inner residues and the beginning residues of rabbit homology strcture PrP(120–229)
(6EPA.pdb) and NMR structure PrP(124–228) (2FJ3.pdb) but mouse PrP has no such an
Arginine residue at the end of C-terminal owning this property [44, 45].
Dogs were reported in 2008 to be resistant to infection from prion diseases from other
species [46]. In our recent work [47], MD studies were done under 450 K in explicit sol-
vent, neutral and low pH environments, with heatings using the Langevin thermostat algo-
rithm in constant NVT ensembles and the equilibrations and productions using Langevin
thermostat algorithm in constant NPT ensembles. In the hydrophobic region 121–136 of
dog PrP, MD studies find that there are strong HBs S132–Y163–Y128 linking the two
antiparallel β-strands, and strong HPs M134–A133, M129–L130, V121–V122 residing
in the core of the hydrophobic region 121-136 [47]. We should note that residue 129 for
dog PrP is L129 (http://www.uniprot.org/uniprot/O46501) but for many others is M129.
For the hydrophobic region PrP(109–136), we should also notice the following points:
(1) the segment GYMLGS or GYVLGS of HuPrP(127–132) can form Class 8 an-
tiparallel amyloid fibrils (3NHC.pdb and 3NHD.pdb) [8, 48],
(2) the mutants A117V and M129V cause GSS [49, 50, 51] and CJD [52, 53]
respectively,
(3) the β-sheet core of PrPSc consists of three layers of β-strands E1(116–119),
E2(129–132) and E3(160–164) [54], where E1 and E2 are in the hydrophobic re-
gion (109–136),
(4) H111 is a residue of copper binding sites [55, 56, 57, 58],
(5) Y128 is in the center of HB-and-SB-network of HB(Y128–D178), SB(D178–
R164), HB(Y128–R164), HB(Y128–H177), HB(H177-N154) [59, 60, 61, 62],
(6) A133 and S132 have HBs with R220 and a water binding site with G131 [63,
64], in PrP(113–132) the hydrophobic cluster with vdWs rendering of atoms in
residues 113–127 interacts with the first β-strand (see Figure 2(B) of [65]), M129
makes interactions with the side chain of V122 and pulls the N-terminus into the
β-sheet [61] and M129 is very close to Y163 [31],
(7) conservation of the Gly-rich region PrP(119–131) is required for uptake of prion
infectivity [3, 66, 67] is shown by the physical or chemical properties of numerous
mutations in the PrP(119–131) Gly-rich region [3],
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(8) one O-linked sugar at Ser135 can affect the coil-to-β structural transition of the
prion peptide, but at Ser132 the effect is opposite [68], etc., and
(9) the NMR structure of HuPrP(110–136) in dodecylphosphocholine micelles was
known (2LBG.pdb) [69] and we do MD simulations for it as follows.
We used the ff03 force field of the AMBER 11 package [70], in a neutral pH en-
vironment. The systems were surrounded with a 12 angstroms’ layer of TIP3PBOX
water molecules and with 2 Cl- ions added using the XLEaP module of AMBER 11.
The templates used are the 2LBG.pdb from the Protein Data Bank and its 17 mutants
at G114V, A117V, G119A, G119L, G119P, A120P, G123A, G123P, G124A, L125A,
G126A, G127A, G127L, M129V, G131A, G131L, G131P, which are got by the mu-
tate module of the free package Swiss-PdbViewer Version 4.1.0 (http://spdbv.vital-it.ch/).
These 18 models were firstly optimized by SD method and then CG method for 2 stages.
Minimization Stage 1 is holding the solute fixed with a force constant of 500.0 kcal mol-1
angstrom-2 for 500 steps of SD minimization followed by 500 steps of CG minimization.
Minimization Stage 2 is minimizing the entire system for 1000 steps of SD minimization
followed by 1500 steps of CG minimization. The minimized models were checked by
Swiss-PdbViewer and found there is not any bad contact that makes amino acids clashed.
Then, the solvated proteins were quickly heated from 0 K to 310 K linearly for 300 ps
and then systems were kept at 310 K for 700 ps. The systems were in constant NVT
ensembles using Langevin thermostat algorithm with weak restraints (a force constant of
10.0 kcal mol-1 angstrom-2) on the solvated proteins. The SHAKE and PMEMD algo-
rithms with nonbonded cutoffs of 12 angstroms were used. Next, the systems were done
MD simulations in constant NPT ensembles (with constant pressure 1 atm and constant
temperature 310 K) under the Langevin thermostat for 4 ns and the PRESS, VOLUME
(DENSITY) and RMSDs were sufficiently stable for each of the 18 models (Figure 7). A
step size of 2 fs was used for all the MD simulations, the structures were saved to file every
1000 steps and the Metropolis criterion was used. These MD simulation conditions are
completely consistent with the experimental work of NMR structure of HuPrP(110–136)
(2LBG.pdb).
We picked out the snapshots at 0, 1, 2, 3, 4 and 5 ns for each model (Figure 8) and
found the α-helix structure of each model has been unfolding and longer MD simulations
might make the α-helix structure unfolded completely (Figures 8∼9). This shows that
the structure in PrP(110–136) region is structurally unstable and might be critical to the
conversion from the predominantly α-helical PrPC into the rich β-sheet PrPSc.
The preliminary findings to explain the above performance during the 5 ns of MD
simulations may be described as follows. At the beginning of the simulations, the 3D
structures of all the 13 models are α-helices (Figures 8∼9). with rich HBs. In an ideal α-
helix, there are 3.6 residues per complete rotating so a rotation of 100 degrees per residue.
Thus, in all the 13 models, there are about 7 turns (Figure 8) in each α-helix. A α-helix is
maintained by HBs. Clearly, the disappearance of HBs is a reason for the unfolding of all
the 13 models. As the progress of MD simulations, most of them have disappeared, except
for the three main HBs GLY/ALA/LEU/PRO131–SER135–ARG136, TYR128–SER132,
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Figure 7: Variations of the potential energy (EPTOT), kinetic energy (EKTOT),
total energy (ETOT), temperature, pressure, volume, density, and RMSDs during
the 5 ns of MD simulations for all the models. In the RMSD graph, different colors
stand for HuPrP(110–136) and its 17 mutants.
which have different occupied rate for each model (Table 1) and are just in the N-terminal
of the structural region of HuPrP(125–228) (1QLX.pdb). This might show that PrP(110–
124) region of PrP(110–136) (2LBG.pdb) is very unstable. We also found that there is
a SB between HIS111–LYS110 with the occupied rate 100% for the 13 models. Spe-
cially for the mutants G127L, M129V, G131A, and G131L, there is another SB between
HIS111–136ARG linking the head and tail of HuPrP(110–136). Seeing the snapshots
of 3, 4 and 5 ns of mutant G127L in Figure 8, 4 and 5 ns of mutant M129V in Figure
8, 3, 4 and 5 ns of mutant G131A in Figure 8, and 3, 4 and 5 ns of mutant G131L in
Figure 8, we may know the SB HIS111–136ARG makes these snapshots looking like a
“hairpin”. HIS111 is a very important residue in PrP(110–136). Along with the unfold-
ing of α-helical structure of all these 13 models, we found many HPs disappeared except
for some fundamental ones MET134–ALA133, LEU130–129MET, VAL122–VAL121-
ALA120, ALA118–ALA117–ALA116–ALA115, and ALA113–MET112 with the oc-
cupied rate 100%, where ALA118–ALA117–ALA116–ALA115 are in the core of the
palindrome AGAAAAGA and this might imply to us the hydrophobic core is very hard
to break and this palindrome really has enormous potential to be amyloid fibrils.
4 Concluding Remarks on PrP(109–136)
To really reveal the secrets of prion diseases is very hard. For us it is a long shot but
certainly worth pursuing. It was reported that the hydrophobic region PrP(109–136) con-
trols the formation into diseased prions: the AGAAAAGA palindrome and Glycine-xxx-
15
Figure 8: The respective snapshots at 0 ns, 1 ns, 2 ns, 3 ns, 4 ns and 5 ns of the
MD simulations for the 18 models. The dashed lines denote hydrogen bonds.
Glycine repeats (both being the inhibitor of prion diseases) are just in this region. This
paper gives some investigations and explanations on the PrP(109–136) region in view of
its 3D structures and molecular dynamics studies. The structural bioinformatics presented
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Figure 9: Variations of the secondary structures of the 18 models. H is the α-helix,
B is the residue in isolated β-bridge, E is the extended strand, G is the 3-helix or
3/10 helix, I is the pi-helix, T is the hydrogen bonded turn and S is the bend as
described in the DSSP program [71].
in this paper can be acted as a reference in 3D images for laboratory experimental works.
This presents some clue or hints for the author to study prion proteins and prions.
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